Dr. Reddy's Laboratories Ltd (RDY) Stock Price & How to Invest

Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is one of the largest Indian pharmaceutical companies, spanning active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. Its therapeutic focus areas include gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology, and its major markets are the United States, India, Russia and CIS, Europe, and emerging markets. The US generics arm (Dr. Reddy's Laboratories, Inc., based in Princeton, New Jersey) is the single largest revenue contributor, and the company trades on the NYSE as an American Depositary Receipt (ADR) while also listing in India.

The FY2026 investment picture is defined by a transition. Dr. Reddy's limited-competition window on generic Revlimid (lenalidomide) ended on January 31, 2026, removing an outsized, high-margin US profit stream (previously estimated near $250 million of quarterly revenue), which crushed Q4 FY26 margins and profit. Management is pivoting toward biosimilars (denosumab, rituximab), generic GLP-1 weight-loss and diabetes therapy (semaglutide, launched in Canada and India), and the acquired ex-US Nicotinell nicotine-replacement consumer-health business bought from Haleon. The core company remains solidly profitable and cash-generative, so the debate is about the pace and quality of growth that replaces the Revlimid windfall.

The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. US generic drug pricing is chronically deflationary and highly competitive, so new launches must run fast just to stand still. Biosimilar and GLP-1 ambitions face regulatory, manufacturing, and competitive execution risk, and any US FDA inspection or compliance issue at a plant could disrupt supply. As an ADR, US investors also carry currency (rupee/dollar) and India-specific regulatory and disclosure exposure. Shelf-stock-adjustment and price-reduction charges (a roughly $50 million revenue reduction on lenalidomide in Q4 FY26) show how quickly pricing dynamics can hit reported results.

5 analysts publish price targets on RDY, averaging $13.51 against a $11.85 price as of August 2026, or +14.0%. The published targets run from $11.53 to $15.78, a moderate spread, and the ratings split 2 buy, 2 hold, 1 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RDY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Dr. Reddy's Laboratories Ltd. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Biosimilars ramp. Dr. The most optimistic published target, $15.78, assumes this works close to its best case.

The case against. The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. The most pessimistic target, $11.53, is roughly what RDY is worth if this bites instead.

Read the full bull and bear case on RDY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Dr. Reddy's Laboratories Ltd's investor relations page or your broker.

• Revenue (FY26): ~$4.0B
• Market cap: ~$12.8B
• P/E (normalized): ~27x
• FY26 EBITDA margin: ~22.8%
• Forward dividend yield: ~0.6%
• FY26 revenue growth: ~3.2%

FY2026 (year ended March 31, 2026) revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, but Q4 profit before tax collapsed to about 2.6% of revenue as the Revlimid exclusivity ended and margins compressed. The stock trades around a mid-20s price-to-earnings multiple with a low payout ratio (near 15%) and a modest sub-1% dividend yield. Figures are approximate, converted from Indian rupee reporting, and can shift with exchange rates and each quarterly release.

Other names that sit close to RDY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RDY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RDY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RDY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

RDY is a profitable, cash-generative global generics maker navigating a well-flagged Revlimid earnings cliff, and its trajectory hinges on how fast its biosimilar, GLP-1, and consumer-health pivots scale.

Whether RDY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RDY a buy or a sell?, and where the stock could go from here in the RDY stock forecast.

For income investors, whether RDY pays a dividend and how the payout looks is covered in does RDY pay a dividend? And to weigh RDY against a peer, read the full side-by-side comparisons: RDY vs VTRS and RDY vs AMRX.